Albireo Pharma Inc
ALBO
ALBO was delisted on the 2nd of March, 2023.
43 hedge funds and large institutions have $17.8M invested in Albireo Pharma Inc in 2014 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 16 increasing their positions, 9 reducing their positions, and 5 closing their positions.
78% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 9
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
5% more funds holding
Funds holding: 41 → 43 (+2)
8% less capital invested
Capital invested by funds: $19.3M → $17.8M (-$1.56M)
85% less call options, than puts
Call options by funds: $60K | Put options by funds: $394K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$1M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$861K |
| 3 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$733K |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$626K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$267K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VM
VHCP Management
New York
|
-$2.73M |
| 2 |
Millennium Management
New York
|
-$1.94M |
| 3 |
FNYS
First New York Securities
New York
|
-$1.43M |
| 4 |
O
OrbiMed
New York
|
-$447K |
| 5 |
VAM
Visium Asset Management
New York
|
-$436K |
ALBO Hedge Fund Activity: Q1 2014 in Review
43 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Albireo Pharma Inc (ALBO) for Q1 2014, worth a combined $17.8M — down 8% from $19.3M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ALBO positions and 5 closed out — a net gain of 2 holders — while 16 added to existing stakes and 9 trimmed.
The largest buyer was Broadfin Capital, adding an estimated $1M. The largest seller was VHCP Management, exiting entirely with an estimated $2.73M sold.
- 43 institutional investors held Albireo Pharma Inc (ALBO) as of Q1 2014, up from 41 in Q4 2013.
- Funds reported $17.8M of Albireo Pharma Inc stock for Q1 2014, down 8% quarter-over-quarter.
- 7 funds opened new Albireo Pharma Inc positions in Q1 2014 and 5 closed out, a net change of +2 holders.
- The largest Albireo Pharma Inc buyer in Q1 2014 was Broadfin Capital, an estimated $1M added.
- The largest Albireo Pharma Inc seller in Q1 2014 was VHCP Management, an estimated $2.73M sold.
Based on aggregated 13F filings for Q1 2014.